Total Payments
$81,857
2024 Payments
$13,650
Companies
8
Transactions
65
Medicare Patients
60
Medicare Billing
$5,455
Payment Breakdown by Category
Other$38,291 (46.8%)
Consulting$35,514 (43.4%)
Research$4,575 (5.6%)
Travel$2,702 (3.3%)
Food & Beverage$774.74 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,291 | 4 | 46.8% |
| Consulting Fee | $35,514 | 21 | 43.4% |
| Unspecified | $4,575 | 5 | 5.6% |
| Travel and Lodging | $2,702 | 13 | 3.3% |
| Food and Beverage | $774.74 | 22 | 0.9% |
Payments by Type
General
$77,282
60 transactions
Research
$4,575
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Spark Therapeutics, Inc. | $49,728 | 15 | $0 (2024) |
| Janssen Research & Development, LLC | $14,450 | 30 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $5,818 | 6 | $0 (2018) |
| SANOFI US SERVICES INC. | $4,602 | 4 | $0 (2022) |
| Janssen Global Services, LLC | $2,874 | 3 | $0 (2022) |
| Daiichi Sankyo Inc. | $2,714 | 5 | $0 (2018) |
| EyePoint Pharmaceuticals US, Inc. | $1,620 | 1 | $0 (2021) |
| Novartis Pharma AG | $51.47 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,650 | 4 | Spark Therapeutics, Inc. ($10,350) |
| 2023 | $10,445 | 2 | Spark Therapeutics, Inc. ($10,445) |
| 2022 | $20,479 | 10 | Spark Therapeutics, Inc. ($16,353) |
| 2021 | $3,585 | 9 | EyePoint Pharmaceuticals US, Inc. ($1,620) |
| 2020 | $11,154 | 19 | Janssen Research & Development, LLC ($7,950) |
| 2019 | $9,511 | 2 | Spark Therapeutics, Inc. ($8,080) |
| 2018 | $9,138 | 8 | SANOFI-AVENTIS U.S. LLC ($4,738) |
| 2017 | $3,895 | 11 | Daiichi Sankyo Inc. ($1,564) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 08/16/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 07/23/2024 | Spark Therapeutics, Inc. | LUXTURNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,350.00 | General |
| Category: OCULAR | ||||||
| 01/29/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 11/03/2023 | Spark Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $95.05 | General |
| 07/28/2023 | Spark Therapeutics, Inc. | LUXTURNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,350.00 | General |
| Category: OCULAR | ||||||
| 12/06/2022 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,420.00 | General |
| 12/02/2022 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,420.00 | General |
| 11/14/2022 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $1,285.50 | General |
| 01/31/2022 | Spark Therapeutics, Inc. | LUXTURNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $16,160.00 | General |
| Category: OCULAR | ||||||
| 01/25/2022 | Spark Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $23.53 | General |
| 01/25/2022 | Spark Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $6.94 | General |
| 01/24/2022 | Spark Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $64.72 | General |
| 01/19/2022 | Spark Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 01/19/2022 | Spark Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $11.80 | General |
| 01/18/2022 | Spark Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $61.30 | General |
| 11/14/2021 | Janssen Global Services, LLC | — | Food and Beverage | In-kind items and services | $33.74 | General |
| 08/31/2021 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 07/08/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $667.50 | General |
| 07/08/2021 | Janssen Research & Development, LLC | — | Travel and Lodging | Cash or cash equivalent | $75.00 | General |
| 07/08/2021 | Janssen Research & Development, LLC | — | Food and Beverage | Cash or cash equivalent | $7.50 | General |
| 05/13/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $222.50 | General |
| 05/13/2021 | Janssen Research & Development, LLC | — | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| 05/13/2021 | Janssen Research & Development, LLC | — | Food and Beverage | Cash or cash equivalent | $2.50 | General |
| 03/08/2021 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $931.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1/2 SAFETY STUDY IN SUBJECTS WITH CHM (CHOROIDEREMIA) GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VECTOR TO DELIVER THE NORMAL HUMAN CHM GENE [AAV2-HCHM] TO THE RETINA | Spark Therapeutics, Inc. | $2,250 | 2 |
| A Phase 2b, multicenter, double-masked, randomized study evaluating the safety and clinical response of sub-retinal administration of CNTO 2476 in subjects with visual acuity impairment associated with Geographic Atrophy Secondary to Age Related Macular Degeneration | Janssen Research & Development, LLC | $1,200 | 2 |
| A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VECTOR TO DELIVER THE NORMAL HUMAN CHM GENE AAV2-HCHM TO THE RETINA | Spark Therapeutics, Inc. | $1,125 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 11 | 11 | $3,828 | $1,117 |
| 2022 | 1 | 17 | 20 | $4,980 | $1,331 |
| 2021 | 1 | 21 | 30 | $7,200 | $1,829 |
| 2020 | 1 | 11 | 17 | $4,301 | $1,179 |
Total Patients
60
Total Services
78
Medicare Billing
$5,455
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Established patient complete exam of visual system | Office | 2023 | 11 | 11 | $3,828 | $1,117 | 29.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 17 | 20 | $4,980 | $1,331 | 26.7% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 21 | 30 | $7,200 | $1,829 | 25.4% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2020 | 11 | 17 | $4,301 | $1,179 | 27.4% |
About Dr. John Stout, MD
Dr. John Stout, MD is a Ophthalmology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770537441.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Stout, MD has received a total of $81,857 in payments from pharmaceutical and medical device companies, with $13,650 received in 2024. These payments were reported across 65 transactions from 8 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($38,291).
As a Medicare-enrolled provider, Stout has provided services to 60 Medicare beneficiaries, totaling 78 services with total Medicare billing of $5,455. Data is available for 4 years (2020–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Houston, TX
- Active Since 05/19/2006
- Last Updated 01/22/2024
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1770537441
Products in Payments
- LUXTURNA (Biological) $44,940
- SAR422459 (Drug) $5,818
- YUTIQ (Drug) $1,620
- NO PRODUCT DISCUSSED (Drug) $1,431
- RTH258A (Drug) $51.47
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Houston
Stephen Slade, M.d, M.D
Ophthalmology — Payments: $1.5M
Ophthalmology $1.5M
Dr. Christina Weng, M.d., M.b.a, M.D., M.B.A
Ophthalmology — Payments: $635,330
Ophthalmology $635,330
Zaina Al-Mohtaseb, Md, MD
Ophthalmology — Payments: $559,665
Ophthalmology $559,665
Dr. John Micheletti, M.d, M.D
Ophthalmology — Payments: $555,738
Ophthalmology $555,738
David Brown, M.d, M.D
Ophthalmology — Payments: $488,095
Ophthalmology $488,095
Dr. Douglas Koch, M.d, M.D
Ophthalmology — Payments: $457,260
Ophthalmology $457,260